Dermatitis, Atopic
Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis
Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody
Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures
Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis
Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment
Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement
FDA Approves Expanded Use of VTAMA and Nemluvio for Atopic Dermatitis Treatment
FDA approval, atopic dermatitis, VTAMA, Nemluvio, Galderma, Organon, dermatology, skin conditions
Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics
Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics
Organon Expands Dermatology Portfolio with $1.2B Acquisition of Dermavant and VTAMA Cream
Organon, Dermavant, VTAMA cream, dermatology, acquisition, steroid-free skin cream, plaque psoriasis, atopic dermatitis
Organon Expands Dermatology Portfolio with Acquisition of Dermavant for Up to $1.2 Billion
Organon, Dermavant, Roivant, dermatology, VTAMA cream, tapinarof, plaque psoriasis, atopic dermatitis, acquisition
FDA Approves Lilly’s Ebglyss for Moderate-to-Severe Atopic Dermatitis
Ebglyss, atopic dermatitis, eczema, FDA approval, Eli Lilly, lebrikizumab, biologic treatment
FDA Approves Ebglyss (Lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis in Adults and Children 12 Years and Older
Ebglyss, Lebrikizumab-lbkz, FDA Approval, Moderate-to-Severe Atopic Dermatitis, Eczema Treatment
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist